Physicians' Academy for Cardiovascular Education

What is the best antithrombotic treatment post-PCI?

3' education - Sep. 21, 2023 - Marco Valgimigli, MD, PhD

Study with traditional Chinese medicine in HFrEF: what's the next step?

3' education - Sep. 21, 2023 - Joseph Wu, MD, PhD

Inorganic nitrate reduces risk of contrast-induced nephropathy after coronary angiography

3' education - Sep. 21, 2023 - Dan Jones, MD, PhD

Effect of SGLT2i on diuretic efficacy in acute heart failure

3' education - Sep. 21, 2023 - Zachary Cox - Nashville, TV, USA

Challenges in ASCVD reduction and TG-related risk

10' education - Sep. 20, 2023 - Erik Stroes, MD, PhD

HCM: Understanding the condition

10' education - Sep. 18, 2023 - Perry Elliott, MD

Unmet needs in lowering LDL-c

10' education - Sep. 14, 2023 - Stephen Nicholls, MD, PhD

The evolving need and challenges to reach LDL-c targets in high-risk patients

10' education - Sep. 14, 2023 - Kausik Ray, MD

Hypertrophic cardiomyopathy: What are the concerns?

10' education - Sep. 14, 2023 - Antonis Pantazis, MD

Artificial intelligence for the management of HF

3' education - Sep. 14, 2023 - Folkert Asselbergs, MD, PhD & Pascal Burger, MD

In which patients is treatment with icosapent ethyl most beneficial?

3' education - Sep. 12, 2023 - Pascal Burger, MD

Combined ESC guidelines for the entire ACS spectrum

3' education - Sep. 11, 2023 - Borja Ibáñez, MD, PhD

Transformation of treatment strategies for ATTR amyloidosis

3' education - Sep. 11, 2023 - Marianna Fontana, MD, PhD

A pragmatic trial of natriuresis-guided use of loop diuretics in acute HF

3' education - Sep. 11, 2023 - Kevin Damman, MD, PhD

First ESC guidelines on cardiomyopathies - management

5' education - Sep. 11, 2023 - Juan Pablo Kaski, MD

First ESC guidelines on cardiomyopathies - diagnosis

5' education - Sep. 11, 2023 - Elena Arbelo, MD, PhD

Update of ESC guidelines on heart failure in a nutshell

5' education - Sep. 4, 2023 - Theresa McDonagh, MD

Large study assessing long-term efficacy and safety of PCSK9 siRNA

3' education - Sep. 4, 2023 - R. Scott Wright, MD

No increase of glucose levels with bempedoic acid

3' education - Sep. 4, 2023 - Kausik Ray, MD

Main messages of new ESC guidelines for CVD management in diabetes

3' education - Aug. 29, 2023 - Nikolaus Marx, MD

What is the best antithrombotic treatment post-PCI?

3' education - Sep. 21, 2023 - Marco Valgimigli, MD, PhD
**ESC Congress 2023** Marco Valgimigli gives his view on the results of the STOPDAPT-3 study and discusses the added value of the insights from this study in the optimization of antithrombotic therapy post-PCI.

ESC Congress 2023 Marco Valgimigli gives his view on the results of the STOPDAPT-3 study and discusses the added value of the insights from this study in the optimization of antithrombotic therapy post-PCI.

Global association of the PURE healthy diet score with health outcomes

Literature - Sep. 21, 2023 - Mente A, et al. - Eur Heart J. 2023
Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

Study with traditional Chinese medicine in HFrEF: what's the next step?

3' education - Sep. 21, 2023 - Joseph Wu, MD, PhD
**ESC Congress 2023** In the QUEST study, the effect of qiliqiangxin was investigated in patients with HFrEF. Dr. Joseph Wu, president of the American Heart Association, shares his thoughts on the study and discusses which further studies are necessary.

ESC Congress 2023 In the QUEST study, the effect of qiliqiangxin was investigated in patients with HFrEF. Dr. Joseph Wu, president of the American Heart Association, shares his thoughts on the study and discusses which further studies are necessary.

Consistent benefit of SGLT2 inhibitors on CV outcomes across various patient populations

Literature - Sep. 21, 2023 - Usman MS, et al. - J Am Coll Cardiol. 2023

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

Inorganic nitrate reduces risk of contrast-induced nephropathy after coronary angiography

3' education - Sep. 21, 2023 - Dan Jones, MD, PhD
**ESC Congress 2023** The randomized NITRATE-CIN study found that dietary intake of inorganic nitrate reduced the risk of contrast-induced nephropathy by 70%, and improved renal and cardiovascular outcomes.

ESC Congress 2023 The randomized NITRATE-CIN study found that dietary intake of inorganic nitrate reduced the risk of contrast-induced nephropathy by 70%, and improved renal and cardiovascular outcomes.

Effect of SGLT2i on diuretic efficacy in acute heart failure

3' education - Sep. 21, 2023 - Zachary Cox - Nashville, TV, USA
**ESC Congress 2023** Zachary Cox shares the results of the DICTATE-AHF trial, which investigated whether early initiation of dapagliflozin within 24h of AHF hospitalization would improve diuretic efficacy.

ESC Congress 2023 DICTATE-AHF investigated whether early initiation of dapagliflozin within 24h of AHF hospitalization would improve diuretic efficacy. Zachary Cox shares the results of this study.

Challenges in ASCVD reduction and TG-related risk

10' education - Sep. 20, 2023 - Erik Stroes, MD, PhD

"What is hypertriglyceridemia? We have to think particles", says Erik Stroes. In this video, he explains the relationship between triglyceride-risk lipoproteins and atherogenic risk.

Phase 2 study with FXI inhibitor in AF stopped early due to overwhelming efficacy

News - Sep. 19, 2023

The AZALEA-TIMI 71 trial, in which the efficacy of the factor XI/XIa inhibitor abelacimab was compared with rivaroxaban in patients with AF at moderate-to-high risk of stroke, has been stopped early due to an overwhelming reduction in bleeding.

HCM: Understanding the condition

10' education - Sep. 18, 2023 - Perry Elliott, MD
Perry Elliott gives a brief overview on the history, diagnosis, imaging, and genetics of hypertrophic cardiomyopathy (HCM).

Perry Elliott gives a brief overview on the history, diagnosis, imaging, and genetics of hypertrophic cardiomyopathy (HCM).

Higher circulating levels of EPA, but not DHA, associated with lower MACE risk

Literature - Sep. 18, 2023 - Le VT, et al - Front Cardiovasc Med. 2023

In an observational cohort study, higher plasma levels of eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), were associated with a lower 10-year risk of MACE. Adjustment for DHA level increased the protective effect of higher EPA levels.

NT-proBNP predicts risk of incident ventricular arrhythmias in adults with an ICD

Literature - Sep. 18, 2023 - Sourour N, et al. - Clin Cardiol. 2023

In the biomarker study of SMASH 1, the authors demonstrated that NT-proBNP concentrations at baseline predict the risk of incident ventricular arrhythmias in adults with an ICD, independently of established risk factors.

Angiographic stenosis regression with PCSK9 inhibitor in acute MI

Literature - Sep. 14, 2023 - Bär S, et al. - EuroIntervention. 2023

A prespecified substudy of the PACMAN-AMI trial showed 1 year of alirocumab, on top of rosuvastatin, resulted in regression of the angiographic diameter stenosis of non-obstructive coronary lesions in acute MI patients, compared with an increase with placebo.

Agenda